Trials / Recruiting
RecruitingNCT07345494
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Ascendis Pharma A/S · Industry
- Sex
- Female
- Age
- 15 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palopegteriparatide | Palopegteriparatide prescribed as per normal clinical practice |
Timeline
- Start date
- 2026-02-18
- Primary completion
- 2036-01-01
- Completion
- 2036-01-01
- First posted
- 2026-01-15
- Last updated
- 2026-03-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07345494. Inclusion in this directory is not an endorsement.